Introduction {#sec1-1}
============

Ebola, earlier termed as Ebola hemorrhagic fever (EHF), is a critically lethal ailment which primarily affects the humans and nonhuman primates. Ebola virus disease (EVD) occurs due to a virus infection which belongs to the family *Filoviridae* and genus *Ebolavirus*.\[[@ref1]\] EVDs has posed diagnostic challenges and has been a universal public health threat since its discovery. While investigating an alleged yellow fever case, Dr. Peter Piot in the year 1976 first detected the disease in Zaire, Africa (presently the Democratic Republic of Congo).\[[@ref2]\] The name "Ebola" was termed as the disease was noticed near the Ebola river in Congo.\[[@ref3]\]

Fruit bats of *Pteropodidae* family, such as *Hypsignathus monstrous, Epomops franqueti*, and *Myonycteris torquata* serve as the natural hosts of the EBOV in Africa. Nonhuman primates may develop the infection by eating the partly eaten fruits and may also transmit the infection to humans.\[[@ref4]\] Indian population is an impending threat to EVD, as India falls in the home range of *Pteropodidae* family of fruit bats.\[[@ref5]\]

Ebola virus transmission primarily takes place through close bodily contact with the infected patient or their fluids, contaminated tissue surfaces, and clothing from alive, infected or deceased individuals. Unsafe traditional burial practices also play a pivotal role in the disease transmission.\[[@ref6]\] There is documented evidence regarding the sexual mode of disease transmission, although transmission through the air is unlikely.\[[@ref7]\]

EVD present with bizarre and atypical manifestations mimicking other viral diseases, especially in the initial disease phase. Constitutional symptoms, such as fever, myalgia, headache, vomiting, and diarrhea are the early presenting features. Hemorrhagic rash, internal and external bleeding are usually the warning manifestations in the late stages.\[[@ref8]\] Bleeding from the body apertures is a distinguishing EVD manifestation.\[[@ref9]\] Gum bleeding, odynophagia, and atypical oral manifestations constitute the oral features of EVD.\[[@ref10]\]

Till date, there is no precise antiviral management or vaccination for EVD. The management protocol mainly relies on supportive and symptomatic therapy, along with monitoring coagulopathies and multiorgan dysfunction.\[[@ref2]\]

The World Health Organization (WHO) affirmed the EVD outbreak as a "Public Health Emergency of International Concern" on August 8^th^, 2014.\[[@ref5]\]

With the enormous immigrant population, India is estimating the likelihood of a probable EVD outbreak. The Ministry of Health and Family Welfare, Government of India, in collaboration with other agencies has appraised the situation and recommended travel instructions by air, land, and sea and health care professionals.\[[@ref11]\]

Taxonomy {#sec1-2}
========

The virus belongs to the *Ebola virus* genus, *Filoviridae* family, and *Mononegavirales* order.\[[@ref12]\] The genus *Ebolavirus* includes the following species- *Zaire ebolavirus* (EBOV), *Reston ebolavirus* (RESTV), *Bundibugyo ebolavirus* (BDBV), *Taï Forest ebolavirus* (TAFV), *Sudan ebolavirus* (SUDV), and the newly identified *Bombali ebolavirus* (BOMV).\[[@ref13]\] Except for exclusive identification of RESTV in the Philippines, all the other species causes endemic West African EVD.\[[@ref14]\]

EBOV responsible for the EHF causes the highest human mortality (57%--90%), followed by SUDV (41%--65%) and Bundibugyo virus (40%). TAFV has caused only two nonlethal human infections to date, whereas RESTV causes asymptomatic human infections.\[[@ref15]\]

[Figure 1](#F1){ref-type="fig"} shows the taxonomy of Ebola virus.

![Taxonomy of Ebola virus](JFMPC-8-2189-g001){#F1}

Transmission {#sec1-3}
============

Based on the Centers for Disease Control and Prevention (CDC) classification, Ebola virus is considered as a biosafety level 4 and category A bioterrorism pathogen with an immense likelihood for massive nationwide transmission.\[[@ref16]\]

Source of Infection {#sec1-4}
===================

Intimate physical contact with the patients in the acute disease stages and contact with the blood/fluids from the dead individuals constitutes the most important modes of transmission.\[[@ref17]\]

The long-established funeral ceremonies in the African countries entail direct handling of the dead bodies, thus significantly contributing to the disease dissemination. Unsafe conventional burial procedures accounted for 68% infected cases in 2014 EVD outburst of Guinea.\[[@ref18]\]

EBOV RNA may be identified for up to a month in rectal, conjunctival, and vaginal discharges and semen specimens may demonstrate the virus presence up to 3 months, thus signifying the presence of EBOV in recuperating patients.\[[@ref14]\] The sexually transmitted case of EVD has been reported between a convalescent patient and close family member. Another study demonstrated a case in a recuperating male patient. The patient\'s semen specimen tested positive with Ebola viral antigen almost 3 months after the disease onset.\[[@ref19]\]

Asymptomatic EBOV carriers are not infectious and do not have a major role play in the EVD outburst, and the field practice in Western Africa supported this assumption.\[[@ref20]\] However, this presumption was refuted after the documentation of a pioneer asymptomatic carrier case in North Gabon epidemic (1996).\[[@ref21]\]

EBOV has been detected from blood, saliva, semen, and breast milk, while RNA has been isolated from sweat, tears, stool, and on the skin, vaginal, and rectal swabs, thus highlighting that exposure to infected blood and bodily secretions constitute the major means of dissemination.\[[@ref22]\]

Eating uncooked infected animal meat such as bats or chimpanzees account significantly to oral EVD transmission, especially in the African countries.\[[@ref23]\] The demonstration of the Ebola virus in the Filipino pigs in 2008 triggered the likelihood of an extensive range of possible animal hosts.\[[@ref24]\]

EVD dissemination has also been reported with hospital-acquired infections, particularly in areas with poor hygiene conditions. The infected needles usage was responsible for the 1976 EVD outbreak in Sudan and Zaire.\[[@ref25][@ref26]\] Improper hygiene and sterilization were the crucial factors for the 1967 Yambuku EVD outburst.\[[@ref27]\]

EVD dissemination may also occur through the inanimate materials with infected body secretions (fomites).\[[@ref19]\] However, disease transmission through the airborne and droplet infection is ambiguous.\[[@ref10]\]

[Figure 2](#F2){ref-type="fig"} shows the primary and secondary transmission of disease.
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[Table 1](#T1){ref-type="table"} depicts the possible routes of transmission.

###### 

Possible routes of transmission

  Mode of transmission                                                                        Consensus likelihood of occurring                                                            Known facts                                                                                                                  Unknown facts
  ------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------
  Airborne/aerosol (small droplet/droplet nuclei)                                             Unlikely from epidemiology of disease                                                        EBOV can be aerosolized mechanically and cause lethal disease in nonhuman primates at low concentrations\[[@ref2][@ref3]\]   Ability of the virus to become airborne through respiratory tract in humans and animals.
  Outbreaks contained without airborne precautions in the affected population\[[@ref4]\]      Airborne stability of EBOV in tropical climates.                                                                                                                                                                          
  EBOV detected after 90 min in experimental small aerosols\[[@ref5]\]                        Whether aerosol generating procedures (AGPs) produce EBOV aerosols that cause transmission                                                                                                                                
  Fomites                                                                                     Less likely from environmental sampling                                                      Virus found in dried blood\[[@ref6]\]                                                                                        EBOV stability in tropical climates and on surfaces
  Persists on glass and in the dark for 5.9 days\[[@ref7]\]                                                                                                                                                                                                                                                             
  Droplet (large droplet)                                                                     Likely from epidemiology and experiments                                                     EBOV found in stool, semen, saliva, breast milk\[[@ref6]\]                                                                   Whether infectious fluids are formed into droplets by humans
  Accidental infections in nonhuman primates, possibly from power washing\[[@ref8][@ref9]\]                                                                                                                                                                                                                             
  Range of droplets containing EBOV.                                                                                                                                                                                                                                                                                    
  EBOV infections without direct contact\[[@ref10]\]                                                                                                                                                                                                                                                                    
  Bodily fluids contact                                                                       Very likely from epidemiology and experimental data                                          Sharing needles and handling the deceased or sick are high risk factors\[[@ref11]\]                                          How much virus is shed in different fluids
  EBOV found in a variety of bodily fluids\[[@ref6]\]                                                                                                                                                                                                                                                                   

Epidemiology {#sec1-5}
============

The vast majority of EVD cases and outbursts have been endemic to African continent ever since the disease detection in 1976,\[[@ref28]\] and 36 such outbreaks have occurred in six African countries.\[[@ref29]\]

[Table 2](#T2){ref-type="table"} shows Ebola epidemiological outbreaks between 1976 and 2014.

###### 

Ebola outbreaks between 1976 and 2014 (Adapted from WHO 2014)

  Year        Country/village                        Ebola virus subtype   Number of human cases   Number of deaths   Mortality   Source and spread infection
  ----------- -------------------------------------- --------------------- ----------------------- ------------------ ----------- --------------------------------------------------------------------------------------------------------------
  1976        Sudan, Nzara and Marida                Sudan virus           284                     151                53%         Close contact within hospitals, infecting many hospital staff
  1976        Zaire, Yambuku                         Ebola virus           318                     280                88%         Contaminated needles and syringes in hospitals
  1976        England                                Sudan virus           1                       0                              Laboratory infection; accidental stick of contaminated needles
  1977        Zaire, Tandala                         Sudan virus           1                       1                  100%        Noted retrospectively
  1979        Sudan, Nzara and Marida                Sudan virus           34                      22                 65%         Recurrent outbreak at the same site as 1976
  1989        USA, Virginia, Pennsylvania            Reston virus          0                       0                              Ebola virus was introduced in to quarantine facility by monkeys from the Philippines
  1989-1990   Philippines                            Reston virus          3                       0                              Source: Macaques from USA. Three workers (animal facility) developed antibodies, did not get sick.
  1990        USA, Virginia                                                4                       0                              The same to 1989
  1994        Gabon                                  Ebola virus           52                      31                 60%         Initially thought to be yellow fever; identified as Ebola in 1995
  1994        Cote d'Ivoire                          Tai forest virus      1                       0                              Scientist became ill after autopsy on a wild chimpanzee (Tai Forest)
  1995        Democratic Republic of Congo (Zaire)   Ebola virus           315                     250                81%         Case-patient worked in the forest; spread through families and hospitals
  1996        Gabon                                  Ebola virus           37                      21                 57%         Chimpanzee found dead in the forest was eaten by hunters; spread in families
  1996-1997   Gabon                                  Ebola virus                                                                  Case-patient was a hunter from forest camp; spread by cloth contact
  1996        South Africa                           Ebola virus           2                       1                  50%         Infected medical professional travelled
  1996        Russia                                 Ebola virus           1                       1                  100%        Laboratory contamination
  2000-2001   Uganda                                 Sudan virus           425                     223                53%         Providing medical care to Ebola case-patient without using adequate personal protection measures
  2001-2002   Gabon                                  Ebola virus           65                      53                 82%         Outbreak occurred over border of Gabon and Republic of Congo
  2001-2002   Republic of the Congo                  Ebola virus           57                      43                 75%         Outbreak occurred over border of Gabon and Republic of Congo
  2002-2003   Republic of the Congo                  Ebola virus           143                     128                89%         Outbreaks in the district of Mboma and Kelle in Cuvette Quest Department
  2003        Republic of the Congo                  Ebola virus           35                      29                 83%         Outbreaks in the villages of Mboma district, Cuvette Quest Department
  2004        Sudan, Yambia                          Sudan virus           17                      7                  41%         Outbreak concurrent with an outbreak of measles, and several cases were later reclassified as measles
  2004        Russia                                 Ebola virus           1                       1                  100%        Laboratory infection
  2007        Democratic Republic of the Congo       Ebola virus           264                     187                71%         The outbreak was declared on November 20. Last death on October 10
  2007-2008   Uganda                                 Bundibugyo virus      149                     37                 25%         First reported occurrence of a new strain
  2008        Philippines                            Reston virus          6                       0                              Six pig farm workers developed antibodies; did not become ill
  2008-2009   Democratic Republic of the Congo       Ebola virus           32                      15                 47%         Not well identified
  2011        Uganda                                 Sudan virus           1                       1                  100%        The Uganda Ministry of Health informed the public that a patient with suspected Ebola died on May 6^th^ 2011
  2012        Uganda, Kibaale                        Sudan virus           11                      4                  36%         Laboratory tests of blood samples were conducted by UVRI and CDC
  2012        Democratic Republic of the Congo       Bundibugyo virus      36                      13                 36%         This outbreak has no link to the contemporaneous Ebola outbreak in kibaale, Uganda
  2012-2013   Uganda                                 Sudan virus           6                       3                  50%         CDC assisted the ministry of Health in the epidemiology and diagnosis of the outbreak
  2014        Democratic Republic of the Congo       Zaire virus           66                      49                 74%         The outbreak was unrelated to the outbreak of West Africa

UVRI: Uganda Virus Research Institute; CDC: Centers for Disease Control and Prevention

The 2014--2016 EVD started in South East Guinea rural surroundings and eventually became a global public health menace by rapidly disseminating to urban localities and other countries.\[[@ref28]\]

[Figure 3](#F3){ref-type="fig"} depicts the geographical distribution of Ebola virus disease.
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The conducive environmental surroundings of the African continent facilitate EVD endemicity. However, intermittent imported Ebola cases have also been noticed in United States, United Kingdom, Canada, Spain, and Thailand.\[[@ref30][@ref31]\]

[Figure 4](#F4){ref-type="fig"} depicts the distribution of Ebola virus disease in West African Countries.
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Out of the unparalleled globally reported 28,616 cases and 11,310 casualties, Liberia accounted for almost 11,000 cases and over 4,800 deaths.\[[@ref32]\]

[Table 3](#T3){ref-type="table"} shows the statistics of the 2014--16 West African outbreak.

###### 

Statistics of 2014-16 West African outbreak

  WHO report date     Guinea total cases   Guinea total deaths   Liberia total cases   Liberia total deaths   Siera Leone total cases   Sierra Leone total deaths   Total cases   Total deaths
  ------------------- -------------------- --------------------- --------------------- ---------------------- ------------------------- --------------------------- ------------- --------------
  13^th^ APRIL 2016   3814                 2544                  10678                 4810                   14124                     3956                        28616         11310

Pathogenesis {#sec1-6}
============

Ebola viruses penetrate the human body through mucous membranes, skin lacerations/tear, close contact with infected patients/corpse, or by direct parental dissemination.\[[@ref33]\] EBOV has a predilection to infect various cells of immune system (dendritic cells, monocytes, and macrophages), endothelial and epithelial cells, hepatocytes, and fibroblasts where it actively replicates by gene modulation and apoptosis and demonstrate significantly high viremia.\[[@ref34]\] The virus reaches the regional lymph nodes causing lymphadenopathy and hematogenous spread to the liver and spleen promote an active inflammatory response.\[[@ref35]\] Release of chemical mediators of inflammation (cytokines and chemokines) causes a dysregulated immune response by disrupting the vasculature system harmony, eventually causing disseminated intravascular coagulation and multiple organ dysfunction.\[[@ref36]\]

[Figure 5](#F5){ref-type="fig"} demonstrates the pathogenesis of Ebola virus disease.
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Clinical Features {#sec1-7}
=================

Due to the bizarre and atypical manifestations in the initial phase, mimicking dengue fever, typhoid fever, malaria, meningococcemia, and other bacterial infections, EVD poses diagnostic dilemmas.\[[@ref37]\]

The incubation period ranges from 2 to 21 days. However, symptoms usually develop 8--11 days following infection.\[[@ref38][@ref39]\]

The initial disease phase is represented by constitutional symptoms.\[[@ref40]\] High-grade fever of \>38^o^ C is the most frequently reported symptom (85--95%), followed by other vague symptoms such as general malaise (85--95%), headaches (52--74%), dysphagia, sore throat (56--58%), and dry cough.\[[@ref41][@ref42]\] The progressively advanced disease is accompanied by abdominal pain (62--68%), myalgia (50--79%), nausea, vomiting, and diarrhea (84--86%).\[[@ref41]\]

Variety of hemorrhagic manifestations forms an integral component of the late disease phase.\[[@ref38]\] Gastrointestinal tract bleeding manifests as petechiae, hematuria, melena, conjunctival bleeding, contusion, or intraperitoneal bleeding. Mucous membrane and venipuncture site bleeding, along with excess clot formation may also occur. As the features advances with time, the patients experience dehydration, confusion, stupor, hypotension, and multiorgan dysfunction, resulting in fulminant shock and ultimately death.\[[@ref43][@ref44]\]

Maculopapular exanthema constitutes a characteristic manifestation of all Filovirus infection, including EVD.\[[@ref45]\] The rash usually appears during the 5^th^ to 7^th^ day of disease and occur in 25--52% of patients in the past EVD outbreaks.\[[@ref46]\]

[Table 4](#T4){ref-type="table"} shows the clinical manifestations of Ebola virus disease.

###### 

Clinical manifestations of Ebola virus disease

  Days                                              Phase                                                                           Main features                                  Other features
  ------------------------------------------------- ------------------------------------------------------------------------------- ---------------------------------------------- ----------------------------------------------------------------------------------------------------------------------
  O-3                                               Early febrile                                                                   Fever                                          Malaise, fatigue, body ache
  3-10                                              Gastrointestinal                                                                Epigastric pain, nausea, vomiting, diarrhoea   Persistent fever, headache, conjunctival injection, abdominal and chest pain, arthralgia, myalgia, hiccups, delirium
  7-12                                              Shock or recovery                                                               Shock: diminished consciousness or coma        Recovery
  Rapid thread pulse, oliguria, anuria, tachypnea   Resolution of gastrointestinal symptoms, increased apetite, increased energy.                                                  
  ≥ 10                                              Late complications                                                              Gastrointestinal hemorrhage                    Secondary infections: oral/esophageal candidiasis, persistent neurocognitive abnormalities

Although EVD has a number of similar features with other viral hemorrhagic fevers (e.g. dengue), there are differences that set them apart.

[Table 5](#T5){ref-type="table"} depicts the differentiating features of the Ebola virus and dengue virus infection.

###### 

Differentiating features of Ebola and dengue virus infection

  Differentiating features                                                                 Dengue                                                                                                         Ebola
  ---------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------
  Incubation period                                                                        3-14 days                                                                                                      2-21 days
  Etiology                                                                                 RNA virus belongs to the genus Flavivirus of family Flaviviridae                                               RNA virus belongs to the genus Ebola virus of family Filoviridae
  Mode of transmission                                                                     Arthropod borne                                                                                                Direct contact with infected blood/body fluids and environment contaminated with these secretions
  Human-human transmission                                                                 No                                                                                                             Yes
  Mortality                                                                                0.04%-0.05%                                                                                                    50%-90%
  Typical signs and symptoms                                                                                                                                                                              
  Fever                                                                                    Common severely high fever (≥40°) lasts for 4-7 days                                                           Common
  High fever (≥38°)                                                                                                                                                                                       
  Headache                                                                                 Common and high intensity (usually retrobulbar)                                                                Common and high intensity
  Muscle ache and pain                                                                     Common and severely intense (known as break bone fever)                                                        Common
  Nausea and vomiting                                                                      Common                                                                                                         Common
  Ocular involvement                                                                       Nonpurulent conjunctivitis                                                                                     Conjunctival injection; subconjunctival hemorrhage
  Diarrhea                                                                                 Uncommon                                                                                                       Common estimated 5 L or more of watery diarrhea per day, lasting for up to 7 days and sometimes longer
  Bleeding                                                                                 Unusual                                                                                                        Usual
  Bleeding from body orifices is a prominent feature                                                                                                                                                      
  Rash (maculopapular exanthema)                                                           Moderately elevated; initial rash occurs before or during 1-2 days of fever; 2nd rash is seen 3-5 days later   Elevated; occurs during the 5^th^-7^th^ day
  Neurologic complications                                                                 Encephalitis                                                                                                   Persistent neurocognitive abnormalities
  Course of disease                                                                        Dengue can be divided into undifferentiated fever, dengue fever, and dengue hemorrhagic fever.                 Features can be divided into 4 main phases: Early febrile phase, gastrointestinal phase, shock or recovery phase and late complications
  Oral manifestations                                                                      Erythema, crusting of lips, and tongue and soft palatal vesicles are the prominent oral features.              Gingival bleeding, mucosal lesions, and pain during deglutination (odynophagia) are the most characteristic oral signs and symptoms.
  Hemorrhagic bullae, petechiae, purpura, ecchymoses, and bleeding gums may also be seen                                                                                                                  
  Typical blood abnormalities                                                                                                                                                                             
  Platelets                                                                                Low                                                                                                            Low
  White blood cell count                                                                   Low                                                                                                            Low
  Hematocrit                                                                               High                                                                                                           Low
  Hemoglobin                                                                               High                                                                                                           Low
  Aspartate transferase                                                                    Elevated                                                                                                       Elevated
  INTERVENTIONS TO CONTROL THE SPREAD AND DISSEMINATION                                    Control of the vectors and their breeding sites                                                                Avoid direct contact with the infected blood/body fluids and adopting universal infection control measures
  TREATMENT                                                                                Supportive                                                                                                     Supportive
  VACCINE DEVELOPMENT                                                                      In progress                                                                                                    In progress

Orofacial features {#sec2-1}
------------------

Gum bleeding, atypical mucosal lesions, and odynophagia comprise the distinctive oral manifestations. Epistaxis (nasal bleed), bleeding from venipuncture sites, conjunctivitis, and cutaneous exanthema are the other manifestations.\[[@ref9]\] Bleeding tendencies and gum bleeding is not seen in asymptomatic or initial EBOV patients reporting to the dental hospital.

EVD dissemination in the field of oral and dental health may appear nonsignificant; although, probable situations which may pose a risk to dental health professional have been appraised by Samaranayake *et al.*\[[@ref21]\] and Galvin *et al.*\[[@ref10]\]

[Table 6](#T6){ref-type="table"} depicts the various orofacial manifestations of Ebola virus disease

###### 

Orofacial manifestations of Ebola virus disease

  Authors, Year                                             Oral features                                         Other features                                                                                                                                                                                                                             
  --------------------------------------------------------- ----------------------------------------------------- ----------------------------------------------------------------- ------------------------------------------------------------ ----------------------------------------------------------- ----------------------------------------------- ------------------------------------------------------------------------------------------------------------
  Anonymous, 1978a                                          Gingival bleeding (48%)                               Dry oral cavity                                                   Painful throat (sensation of dry rope in the throat) (63%)   Epistaxis                                                   Conjunctivae slightly injected but nonicteric   Measles like desquamation (52%)
  Small aphthous like ulcers                                                                                                                                                                                                                                                                                                                                 
  Posterior pharynx slightly injected                                                                                                                                                                                                                                                                                                                        
  Fissures and open sores of the lips and tongue                                                                                                                                                                                                                                                                                                             
  Anonymous, 1978b                                          Gingival bleeding (23%)                               Herpetiform, grayish exudative patch                              Sore throat (32%)                                            Epistaxis                                                   Conjunctivitis (35%)                            Not reported
  Piot, 1978                                                Gingival bleeding (25.6%)                             Oral throat lesions (73%)                                         Sore throat (sensation of "ball" in the throat) (79.2%)      Epistaxis (16.7%)                                           Conjunctivitis (58.2%)                          Skin rash
  Fissures on the lips                                                                                            Injection sites (6.6%)                                                                                                                                                                                                                     
  Herpetic oral lesions                                                                                                                                                                                                                                                                                                                                      
  Grayish exudative patches on soft palate and oropharynx   Dysphagia                                                                                                                                                                                                                                                                                        
  Sureau PH 1989                                            Gingival and oral bleeding                            Oropharyngeal bleeding ulcerations in the mouth and in the lips   Sore throat                                                  Epistaxis                                                   Hemorrhagic conjunctivitis                      Exanthematous rash on trunk
  Pharyngitis                                               Injection sites                                                                                                                                                                                                                                                                                  
  Dysphagia                                                                                                                                                                                                                                                                                                                                                  
  Bonnet, 1998                                              Diffuse bleeding in the oral cavity (gums & tongue)   Oral thrush like lesions                                          Not reported                                                 Bruises and bleeding at the injection sites (late stages)   Not reported                                    Maculopapular rash and petechiae on flanks and limbs (initially); followed by petechiae on the entire body
  Bleeding cracks on the lips                                                                                                                                                                                                                                                                                                                                
  Bwaka, 1999                                               Not reported                                          Not reported                                                      Odynophagia                                                  Injection sites (5%)                                        Conjunctival injection (47%)                    Maculopapular rash
  Dysphagia                                                                                                                                                                                                                                                                                                                                                  
  Sore throat (58%)                                                                                                                                                                                                                                                                                                                                          
  Ndanbi, 1999                                              Gingival bleeding (30%)                               Oral/mucosal redness (30%)                                        Dysphagia (48%)                                              Epistaxis (4%)                                              Conjuctivitis (78%)                             Cutaneous eruption (4%)
                                                                                                                                                                                    Injection site (30%)                                                                                                     Petechiae (22%)                                 
  Mupere, 2011                                              Gingival bleeding (10%)                               Not reported                                                      Sore throat (10%)                                            Epistaxis (10%)                                             Conjunctival injection (40%)                    Not reported
                                                                                                                                                                                    Injection site (10%)                                                                                                                                                     
  Korepeter, 2011                                           Not reported                                          Pharyngeal Arythema                                               Sore throat                                                  Bleeding from injection/venepuncture site                   Conjuctival                                     Maculopapular or morbilliform (meseales like) rash/or scar letenoid
                                                                                                                                                                                                                                                 Hemorrhage                                                                                                  
  Roddy, 2012                                               Gingival bleeding (4%)                                Not reported                                                      Dysphagia (58%)                                              Epistaxis (8%)                                              Conjuctivitis (50%)                             Rash (12%)
                                                                                                                                                                                    Injection site (8%)                                                                                                                                                      
  Chertow, 2014                                             Not reported                                          Oral ulcers and Thrush                                            Throat pain                                                  Not reported                                                Conjunctival injection                          Not reported
                                                                                                                  Dysphagia                                                                                                                                                                                                                                  
  WHO Ebola response team, 2014                             Bleeding gums (2.3%)                                  Not reported                                                      Dysphagia (32.9%)                                            Unexplained bleeding (18%)                                  Conjuctivitis (20.8%)                           Rash (5.8%)
                                                                                                                  Sore Throat (21.8%)                                               Epistaxis (1.9%)                                                                                                                                                         
                                                                                                                                                                                    Injection site (2.4%)                                                                                                                                                    

Diagnosis {#sec1-8}
=========

EVD patients usually demonstrate altered laboratory parameters based on the stage of the disease.

[Table 7](#T7){ref-type="table"} shows the laboratory findings in Ebola virus disease.

###### 

Laboratory findings in Ebola virus disease

  Timing          Common laboratory findings
  --------------- ---------------------------------------------------------------------------------------------------
  Early illness   Leukopenia, lymphopenia, and thrombocytopenia
                  Elevated hemoglobin and hematocrit
                  Elevated aspartate aminotransferase and alanine aminotransferase (ratio≥3:1)
                  Elevated prothrombin time, activated partial thromboplastin time, and D-dimer
  Peak illness    Leukocytosis, neutrophilia, and anemia
                  Hyponatremia, hypo- or hyperkalemia, hypomagnesemia, hypocalcemia, hypoalbuminemia, hypoglycaemia
                  Elevated creatinine phosphokinase and amylase
                  Elevated blood urea nitrogen and creatinine
                  Elevated serum lactate and low serum bicarbonate
  Recovery        Thrombocytosis

The WHO (2014) recommended the sample collection of whole blood or oral swab at suitable centres called Ebola treatment centers.\[[@ref47]\] Reverse transcriptase polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA) are the most frequently utilized tests for laboratory affirmation of the EVD.\[[@ref43]\] RT-PCR is capable of detecting viral RNA in the blood samples of infected patients immediately after the commencement of signs and symptoms,\[[@ref42][@ref48]\] has a high sensitivity (up to 100%), and gives results within 1--2 days in cases of epidemics. ELISA detects the immunoglobulins G and M in samples of infected patients, has a low sensitivity (91%) and is not suitable for initial affirmation during an outbreak.\[[@ref42][@ref49]\]

Prevention {#sec1-9}
==========

The most imperative strategy in EVD is to avert the vulnerable population from getting infected and limit the transmission. These preventive strategies entail intensive and rigorous endeavors from the Government, public health amenities, medical units, and personals.\[[@ref50]\]

The most essential aspect to curb EVD transmission is to avert direct bodily contact with infected individuals and their body fluids.\[[@ref51]\]

Health caregivers are extremely vulnerable and experience an augmented professional threat for EVD.\[[@ref52]\] Thus, scrupulous adherence to the universal infection control measures is fundamental in all the hospitals, laboratories, and other health care services.\[[@ref53]\] The U.S. CDC has advocated the appropriate use of various personal protective equipment as a mandate for health care professionals.\[[@ref50]\]

The risk of rapid importation of Ebola virus into human beings can be prevented by averting the direct bush meat and bats contact.\[[@ref54]\]

Unsafe traditional burial procedures, especially in the African continent significantly contributed to the EVD transmission. Hence, it is essential to practice safe and guarded funeral rituals to prevent the disease spread.\[[@ref55]\]

WHO recommends the implementation of safe sex practices to combat the sexual transmission of EVD. Strict abstinence or proper and regular condom use in male EVD survivors at least for a period of 12 months of the symptom onset or until their semen has twice tested negative should be followed.\[[@ref56]\]

Dental health care personals are extremely susceptible to EVD as they are in regular contact with blood and saliva during the routine diagnostic procedures. There is no documented case of EVD through saliva till date. A study on the identification of EBOV in oral fluids affirmed that patients presenting with demonstrable serum levels of EBOV RNA also exhibit identifiable salivary levels.\[[@ref57]\] The incubation period for all body fluids including saliva is 21 days; hence, oral health personals are vulnerable to develop the disease if universal infection control protocol is not followed.\[[@ref58]\]

[Table 8](#T8){ref-type="table"} demonstrates the various infection control measures to prevent the Ebola virus spread.

###### 

Infection control measures to prevent Ebola virus spread

  --------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------
  Personal protective equipments (PPE)                                                                                                          Ebola virus infection may be transmitted through broken skin and mucosa.                                                                                    Gown, gloves (possibly double gloves), surgical mask, eye visor/goggles, or face shield to protect conjunctival, nasal, and oral mucosae at the same time.\                                                                                       Strength of the evidence High
                                                                                                                                                                                                                                                                                                            use additional personal protective equipment (such as double gloving, leg covers and disposable shoe covers, when there is contact with blood and bodily fluids                                                                                   

                                                                                                                                                                                                                                                                                                            Choose PPE of exact size.                                                                                                                                                                                                                         

                                                                                                                                                                                                                                                                                                            Gloves or other PPE that becomes contaminated by blood or bodily fluids must be cleaned or changed before touching other instruments or surfaces.                                                                                                 

                                                                                                                                                                                                                                                                                                            Gloved/ungloved hand hygiene. Use alcohol-based hand rub or soap and running water. undertake scrupulous hand cleaning before and after glove use                                                                                                 

  Sharp instruments                                                                                                                             Sharp instruments are extremely dangerous because they become contaminated by blood or bodily fluids and may break skin/mucosae even if protected by PPE.   Use of needles and other sharp instruments must be limited. These instruments must be handled with extreme care and disposed after use in dedicated seal containers.                                                                              Strength of the evidence High

  Nonsharp instruments                                                                                                                          Indirect transmission through nonsharp contaminated instruments is not demonstrated                                                                         Use of disposable medical equipment is recommended or, alternatively, nondisposable medical equipment must be cleaned and disinfected after use according to manufacturer's instructions                                                          Strength of the evidence Low

  Preventive measures are recommended under the                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Precautionary Principle                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  Droplets                                                                                                                                      Airborne transmission is not demonstrated preventive measures are recommended under the precautionary principle                                             If aerosol generating procedures or events, such as coughing or sputum induction, occur, the use of powered air-purifying respirator or respirator (FFP2 or EN certified equivalent or US NIOSH-certified N95) is recommended                     Strength of the evidence Low

  Environmental surfaces                                                                                                                        Environmental surfaces do not pose a risk of infection. However,                                                                                            Use of standard hospital detergents and disinfectants (e.g., 0.5% chlorine solution or a solution containing 5000 ppm available free chlorine), preceded by cleaning to prevent inactivation of disinfectants by organic matter, is recommended   Strength of the evidence Low

  Ebola virus is nonenveloped and is able to survive in the environment for long time.                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  Preventive measures regarding surfaces visibly contaminated with blood and bodily fluids are recommended under the precautionary principle.                                                                                                                                                                                                                                                                                                                                                                                                                 

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  --------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------

[Box 1](#T10){ref-type="table"} shows the travel guidelines to EBOV affected regions.

###### 

Shows the UK Travel guidelines to EBV infested regions.

  ---------------------------------------------------
  • Do not handle dead animals or their raw meat
  • Avoid contact with patients who have symptoms
  • Avoid unprotected sex with people in risk areas
  • Wash fruit and vegetables before eating them
  • Wash hands frequently using soap and water
  ---------------------------------------------------

Treatment {#sec1-10}
=========

Till date, there is no precise antiviral management or vaccination for EVD.\[[@ref51]\] The management protocol mainly relies on supportive and symptomatic therapy. Public health strategies emphasizing on epidemiological surveillance, contact tracing, and quarantine of the patient have been recommended to combat the dissemination of EVD.\[[@ref59]\]

Rehydration, adequate nourishment, analgesics, and blood transfusion form a keystone supportive treatment of EVD patient.\[[@ref60]\] Intravenous fluids and oral rehydration solution endow with proper electrolytes substitute and maintain the intravascular volume. Unrelenting vomiting and diarrhea are taken care of by the use of antiemetics and antidiarrheal drugs.\[[@ref35][@ref60][@ref61]\] Suspected cases of secondary bacterial infections and septicemia are best managed by the use of prophylactic antibiotic regimen (third generation I.V. cephalosporins).\[[@ref62]\] Concurrent parasitic coinfections may also be seen and require prompt investigations and management.\[[@ref63]\]

A number of investigative clinical trials emphasizing on the development of vaccine, antibody therapies, and antiviral drugs have been conducted for EVD.\[[@ref64]\]

[Table 9](#T9){ref-type="table"} shows experimental treatment for Ebola virus disease.

###### 

Experimental treatment for Ebola virus disease

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Drug                                                                                                        Drug type                                                                                         Mechanism of action                                                                  Ebola virus clinical trial phase                                                         Result/status                                                                                         Other clinical trials
  ----------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  FAVIPIRAVIR (T-705) (Fujifilm Holding Corp)                                                                 Nucleotide analogue and viral RNA polymerase inhibitor                                            Prevents viral replication by RNA chain termination and/or lethal mutaggenesis       Phase II (NCT02329054): JIKI; NCT02662855: Sierra Leone)                                 Efficacy in patients with low to moderate levels of virus                                             Administered with ZMapp to a patient who recovered; administered to a patient with convalescent plasma who recovered; retrospective study indicated increased survival and lower viral loads.

  BCX4430 (BioCryst Pharmaceuticals Inc., Durham, NC)                                                         Synthetic adenosine analogue                                                                      Inhibits viral RNA polymerase and results in RNA chain terminaton                    Phase I (NCT02319772)                                                                    Phase I complete; results not available yet                                                           Not Applicable

  TKM-Ebola (Tekmira Pharmaceutical Corp.)                                                                    Small Interfering (si) RNA agents Lipid nano-particle with si RNA-Ebola virus specific compound   Gene silencing                                                                       TKM-100802Phase I (NCT02041715)\                                                         Terminated\                                                                                           100802 administered to two patients in combination with convalescent plasma; both survived
                                                                                                                                                                                                                                                                                                     TKM-130803\                                                                              Terminated early; did not demonstrate efficacy \[77\]; development has been suspended                 
                                                                                                                                                                                                                                                                                                     Phase II (PACTR201501000997429)                                                                                                                                                                

  BrincidofovirCMX001 (Chimerix Durham, NC)                                                                   Nucleotide analogue                                                                               Inhibits viral replication by inhibiting DNA polymerase                              Phase II (NCT02271347)                                                                   Terminated due to low enrollment; not currently under further development as EBOV therapeutic agent   Administered to 5 patients during the outbreak, often in combination with other therapies

  AVI-6002\                                                                                                   Small Interfering (si)\                                                                           Gene silencing                                                                       Phase I\                                                                                 AVI-6002: Favorable safety and tolerability\                                                          Not Applicable
  AVI-7537 (Sarepta Therapeutics Cambridge, MA)                                                               RNA agents\                                                                                                                                                                            AVI-6002: NCT01353027;\                                                                  AVI-7537:\                                                                                            
                                                                                                              Phosporo-diamidate morpholino oligomer Ebola virus specific compound                                                                                                                   AVI-7537: NCT01593072                                                                    Terminated prior to enrollment; further development has been suspended                                

  Z-Mapp (Mapp Pharmaceuticals)                                                                               Combination of 3 different monoclonal antibodies-Ebola specific compound                          Virus neutralisation                                                                 Phase II (NCT02363322)                                                                   Inconclusive efficacy due to insufficient statistical power                                           Administered to patients during the outbreak, often in combination with other therapies

  JK-05 (Sihuan Pharmaceutical Holdings Group Ltd and Academy of Military Medical Sciences (Beijing, China)   Broad spectrum antiviral drug                                                                     Inhibits viral RNA polymease                                                         Not Applicable\                                                                          Not Applicable                                                                                        Not Applicable
                                                                                                                                                                                                                                                                                                     Animal studies completed; now considered for use in emergency situations for Army only                                                                                                         

  Convalescent plasma or blood                                                                                Derived from surviving or cured Ebola patients                                                    contains anti Ebola antibodies                                                       Phase I/II: NCT02333578 Phase II/III (NCT02342171; ISRCTN13990511)                       Completed; results from one study found no improvement in efficacy in treated group                   Whole blood: 1995 Kikwit outbreak---7 out of 8 survivors; administered to patients during the outbreak, often in combination with other therapies

  GS-5732                                                                                                     Small molecule monophosphoramidate prodrug of an adenosine analogue                               Inhibition of RNA-dependent RNA polymerase                                           Phase I                                                                                  Phase I complete; Phase II for efficacy in survivors with viral persistence in semen (NCT02818582)    Administered to a newborn in combination with ZMapp and buffy coat transfusion; patient survived

  IFN- β                                                                                                      Cytokine family member                                                                            Inhibits the viral infection by activating the innate and adaptive immune response   Phase I/II (ISRCTN17414946)                                                              Results not yet released                                                                              Not Applicable

  Amiodarone                                                                                                  Multi-ion channel blocker for treatment of cardiac arrhythmias                                    Inhibits filovirus entry in vitro by reducing virus binding to target cells          Phase II (NCT02307591)                                                                   Terminated early; reduction in case-fatality rate; not statistically significant                      \-

  FX-06                                                                                                       Fibrin derived peptide                                                                            Treats hemorrhagic shock by reducing vascular leakage                                Not Applicable                                                                           Not under current investigation for EBOV indication                                                   2014\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    3-day treatment course (400 mg/kg loading dose+200 mg/kg maintenance dose) was administered to a patient in combination with self-administration of amiodarone and intermittent treatment with favipiravir; patient survived
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Various clinical trials in Africa, Europe, and the United States suggest that Ebola vaccines are in various development stages (Phase I--III). A number of candidate vaccines employ diverse platforms, including recombinant viral vectors (most evolved vaccine candidate), DNA vaccines, inactivated viral particles, subunit proteins, recombinant proteins, and virus-like particles. Example of viral vectors expressing ebolavirus glycoproteins include recombinant simian adenovirus (cAd3), recombinant vaccinia virus, recombinant human adenovirus (Ad26), and a live vesicular stomatitis virus used alone or in prime-booster regimens.\[[@ref65]\]

However, Ebola virus having the glycosylated surface proteins and preferentially infecting the immune cells impedes the development of an effective vaccine.\[[@ref66]\]

Dental Management {#sec1-11}
=================

Dental health care professionals in Europe have not encountered a case of EVD so far. However, health care personals (including dental surgeons) are more prone to EVD while treating patients in West or sub-Saharan Africa. Dental professionals are more likely to encounter asymptomatic EVD patients or those with early-stage vague symptoms.\[[@ref27]\]

Individuals with a travel history to Ebola endemic regions, but with no direct intimate contact with the disease fall in the low-risk category and may undergo any medical/dental health care procedures without restrictions. However, all the nonessential procedures should be postponed for 21 days in individuals with direct exposure to the virus. The regional Health Service Executive Department of Public Health needs to be notified when the exposed patient\'s treatment cannot be deferred or controlled with pharmacotherapy.\[[@ref10]\]

Conclusion {#sec1-12}
==========

EVD has emerged as a significant global public health menace due to multiple disease outbreaks in the last 25 years. Recent advancements are being carried out in the form of effective Ebola virus vaccine and anti-Ebola virus drugs. However, rapid geographic dissemination, nonspecific clinical presentation, lack of vaccine, and specific diagnostic test are the possible challenges to combat this dreaded public health menace.
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